Mesothelioma | Mesothelioma

... Ecopia to Present New Data on ECO-4601's Pharmacokinetic and ADME to the American Association for Cancer Research 'AACR' Close Window Printable Version PRESS RELEASE Ecopia BioSciences Inc.

TSX: EIA INDUSTRY: Medical Email A Friend Add to Hot Off The Wire Signup for Hot Off The Wire MARCH 31, 2006 - 11:37 ET Ecopia to Present New Data on ECO-4601's Pharmacokinetic and ADME to the American Association for Cancer Research 'AACR' MONTREAL, QUEBEC-(CCNMatthews - March 31, 2006) - Ecopia BioSciences Inc.

(TSX:EIA) will be presenting on Monday, April 3rd 2006, data on ECO-4601, its drug candidate for brain cancer, at the 97th annual meeting of American Association for Cancer Research in Washington, D.C.

The data presented in the poster describe data from pharmacokinetic and metabolism studies done in animals.

Dr.

Pierre Falardeau, Ecopia's President and Chief Executive Officer, stated that: "The data which will be presented at this conference were very important in order to define the route and schedule of administration of ECO-4601, our lead drug candidate for treating brain tumours.

This information allows us to define the best way to use ECO-4601 in the clinical setting in order to maximize our chance to highlight the clinical potential of this novel compound." The data presented in the poster reveal that ECO-4601 has a similar half-life in rodents and in non-rodents, and that sustained drug level could be achieved through continuous intraveno...

Read more...